Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib: Is mrcc curable with targeted therapy?

Amishi Y. Shah; Jose A. Karam; Zita D. Lim; Chaan S. Ng; Nizar M. Tannir

doi:10.1016/j.eucr.2014.12.011

Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib: Is mrcc curable with targeted therapy?

Amishi Y. Shah, Jose A. Karam, Zita D. Lim, Chaan S. Ng, Nizar M. Tannir

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

We report a patient with metastatic clear-cell renal cell carcinoma (mRCC) who presented with primary tumor in situ in the left kidney and metastases to bone, liver, lungs, and brain. After over 5 years of sunitinib therapy and subsequent cytoreductive left nephrectomy, the patient achieved radiographic complete response (CR) and had pathologic CR in the nephrectomy specimen. Durable clinical and pathological CRs are possible with targeted agents, even with primary tumor in situ and widely disseminated metastases. Ongoing research will define the optimal duration of systemic therapy in exceptional responders and identify the molecular determinants of response and resistance.

Original language	English (US)
Pages (from-to)	18-20
Number of pages	3
Journal	Urology Case Reports
Volume	3
Issue number	2
DOIs	https://doi.org/10.1016/j.eucr.2014.12.011
State	Published - 2015

Keywords

Brain metastasis
Metastatic renal cell carcinoma
Sunitinib
Tki

ASJC Scopus subject areas

Urology

MD Anderson CCSG core facilities

Clinical Trials Office

Access to Document

10.1016/j.eucr.2014.12.011

Cite this

@article{4ddf2a69d6664074b0cff1a3cb4d8258,

title = "Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib: Is mrcc curable with targeted therapy?",

abstract = "We report a patient with metastatic clear-cell renal cell carcinoma (mRCC) who presented with primary tumor in situ in the left kidney and metastases to bone, liver, lungs, and brain. After over 5 years of sunitinib therapy and subsequent cytoreductive left nephrectomy, the patient achieved radiographic complete response (CR) and had pathologic CR in the nephrectomy specimen. Durable clinical and pathological CRs are possible with targeted agents, even with primary tumor in situ and widely disseminated metastases. Ongoing research will define the optimal duration of systemic therapy in exceptional responders and identify the molecular determinants of response and resistance.",

keywords = "Brain metastasis, Metastatic renal cell carcinoma, Sunitinib, Tki",

author = "Shah, {Amishi Y.} and Karam, {Jose A.} and Lim, {Zita D.} and Ng, {Chaan S.} and Tannir, {Nizar M.}",

note = "Publisher Copyright: {\textcopyright} 2015 The Authors.",

year = "2015",

doi = "10.1016/j.eucr.2014.12.011",

language = "English (US)",

volume = "3",

pages = "18--20",

journal = "Urology Case Reports",

issn = "2214-4420",

publisher = "Elsevier Saunders",

number = "2",

}

TY - JOUR

T1 - Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib

T2 - Is mrcc curable with targeted therapy?

AU - Shah, Amishi Y.

AU - Karam, Jose A.

AU - Lim, Zita D.

AU - Ng, Chaan S.

AU - Tannir, Nizar M.

PY - 2015

Y1 - 2015

N2 - We report a patient with metastatic clear-cell renal cell carcinoma (mRCC) who presented with primary tumor in situ in the left kidney and metastases to bone, liver, lungs, and brain. After over 5 years of sunitinib therapy and subsequent cytoreductive left nephrectomy, the patient achieved radiographic complete response (CR) and had pathologic CR in the nephrectomy specimen. Durable clinical and pathological CRs are possible with targeted agents, even with primary tumor in situ and widely disseminated metastases. Ongoing research will define the optimal duration of systemic therapy in exceptional responders and identify the molecular determinants of response and resistance.

AB - We report a patient with metastatic clear-cell renal cell carcinoma (mRCC) who presented with primary tumor in situ in the left kidney and metastases to bone, liver, lungs, and brain. After over 5 years of sunitinib therapy and subsequent cytoreductive left nephrectomy, the patient achieved radiographic complete response (CR) and had pathologic CR in the nephrectomy specimen. Durable clinical and pathological CRs are possible with targeted agents, even with primary tumor in situ and widely disseminated metastases. Ongoing research will define the optimal duration of systemic therapy in exceptional responders and identify the molecular determinants of response and resistance.

KW - Brain metastasis

KW - Metastatic renal cell carcinoma

KW - Sunitinib

KW - Tki

UR - http://www.scopus.com/inward/record.url?scp=84933677480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933677480&partnerID=8YFLogxK

U2 - 10.1016/j.eucr.2014.12.011

DO - 10.1016/j.eucr.2014.12.011

M3 - Article

C2 - 26120560

AN - SCOPUS:84933677480

SN - 2214-4420

VL - 3

SP - 18

EP - 20

JO - Urology Case Reports

JF - Urology Case Reports

IS - 2

ER -

Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib: Is mrcc curable with targeted therapy?

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this